Compared to Estimates, McKesson (MCK) Q1 Earnings: A Look at Key Metrics

McKesson (MCK) reported $97.83 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 23.4%. EPS of $8.26 for the same period compares to $7.88 a year ago.The reported revenue represents a surprise of +1.82% over the Zacks Consensus Estimate of $96.08 billion. With the consensus EPS estimate being $8.23, the EPS surprise was +0.36%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how McKesson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Revenue- U.S. Pharmaceutical: $89.95 billion versus the four-analyst average estimate of $87.36 billion. The reported number represents a year-over-year change of +25.4%.Revenue- Prescription Technology Solutions: $1.43 billion compared to the $1.35 billion average estimate based on four analysts. The reported number represents a change of +15.6% year over year.Revenue- International: $3.74 billion versus $3.67 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +1.3% change.Revenue- Medical-Surgical Solutions: $2.7 billion versus $2.7 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +2.5% change.Adjusted Operating Profit- U.S. Pharmaceutical: $950 million compared to the $965.96 million average estimate based on four analysts.Adjusted Operating Profit- International: $99 million compared to the $100.22 million average estimate based on four analysts.Adjusted Operating Profit- Medical-Surgical Solutions: $244 million versus $215.97 million estimated by four analysts on average.Adjusted Operating Profit- Prescription Technology Solutions: $269 million versus $249.95 million estimated by four analysts on average.Adjusted Operating Profit- Corporate: $-138 million versus the three-analyst average estimate of $-108.6 million.View all Key Company Metrics for McKesson here>>>Shares of McKesson have returned -2% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Zacks' Research Chief Picks Stock Most Likely to "At Least Double"Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report McKesson Corporation (MCK): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks